Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.
Patients voluntarily agree to participate in this study and sign the informed consent form;
Age ≥ 18 years;
ECOG PS score 0-2;
Pathologically confirmed adenocarcinoma of the stomach/gastroesophageal junction;
Pregnant or lactating women;
Known HER2 positivity;
Patients with adverse events from previous treatments (except alopecia) that have not resolved to ≤ Grade 1 (CTCAE v5.0);
History of other malignant diseases within the past 5 years or concurrent malignant diseases, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix;
Parallel
SHR1701
DrugSHR1701:1800mg,d1,Q3W
SHR2554
DrugSHR2554 350mg,bid
CAPOX
DrugCapecitabine:1000mg/kg,bid,d1-d14,Q3W Oxaliplatin:130mg/m2,d1,Q3W
Apatinib
Drug250 mg, qd
ORR
Click on the lead sponsor to view all of their trials.
